281 episodes

Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.

The Peter Attia Drive Peter Attia, MD

    • Health & Fitness
    • 4.7 • 421 Ratings

Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.

    #241 ‒ Living intentionally, valuing time, prioritizing relationships, and more keys to a rich life | Ric Elias (Part 2)

    #241 ‒ Living intentionally, valuing time, prioritizing relationships, and more keys to a rich life | Ric Elias (Part 2)

    View the Show Notes Page for This Episode
    Become a Member to Receive Exclusive Content
    Sign Up to Receive Peter’s Weekly Newsletter
    Ric Elias, the founder of Red Ventures and previous guest on The Drive, returns to discuss his evolving insights on time, relationships, parenting, and how to make the most of the gift of life. In this episode, he reflects on the changes he’s made since his near-death experience during the crash landing of Flight 1549 on the Hudson River in 2009. Ric reveals many keys to living a rich life, such as aiming for continuous growth, approaching life with true intentionality, and valuing our time in accordance with that. He talks about relationships as the core of a rich life and provides insights on parenting and how we should think about our relationship with our kids as they grow older. Finally, Ric discusses the importance of staying true to yourself, the value in struggle, and finding meaning in helping others.
    We discuss:
    Reflecting on the tumultuous last few years and how his experience on Flight 1549 helped him [2:30]; Parenting: a game of tug of war that you must ultimately lose [5:00]; Importance of friendship and Ric’s motivation for his recent “Friends summit” [8:00]; The impact of looking forward and focusing on growth on finishing life well [13:00]; How our relationships with our children evolve as they grow, and a new perspective on purpose [21:15]; Living with complete intention for a rich life, valuing your time, and other life lessons inspired by Ric’s near-death experience on Flight 1549 [31:15]; How society’s relationship with work has changed, the pros and cons of remote and hybrid working environments, and an update on his company “Red Ventures” [37:45]; Ric’s dedication to philanthropy [44:45]; The Golden Door Scholars program aiming to help undocumented students with education and a future career [50:30]; Ric’s journey in health and longevity [59:15]; Letting go of guilt and loving yourself [1:02:30]; The relationship between happiness and wealth [1:06:45]; Playing the “infinite game,” staying true to oneself, and ignoring the negative [1:09:15]; Speculating on the meaning of success, the drivers of greatness, and the value of struggle [1:16:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

    • 1 hr 22 min
    The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.

    The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.

    View the Show Notes Page for This Episode
    Become a Member to Receive Exclusive Content
    Sign Up to Receive Peter’s Weekly Newsletter
    Dan Rader is a Professor at the Perelman School of Medicine at the University of Pennsylvania, where he conducts translational research on lipoprotein metabolism and atherosclerosis with a particular focus on the function of high-density lipoproteins (HDLs). In this episode, Dan goes in-depth on HDL biology, including the genesis of HDL, its metabolism, function, and how this relates to atherosclerotic cardiovascular disease (ASCVD). He explains why having high HDL-C levels does not directly translate to a low risk of cardiovascular disease and reveals research pointing to a better way to measure the functionality of HDL and predict disease risk. He also goes into detail on the role of HDL in reverse cholesterol transport and the benefits this has for reducing ASCVD. Additionally, Dan discusses the latest thinking around the association between HDL cholesterol and neurodegenerative diseases and ends the conversation with a discussion of how the latest research on HDL provides a promising outlook for ongoing trials and future therapeutic interventions.
    We discuss:
    The lipidology of apoB and apoA [4:00]; A primer on the high-density lipoprotein (HDL): genesis, structure, and more [9:30]; How the lipoprotein system differs in humans compared to other mammals [20:00]; Clarifying the terminology around HDL and apoA [25:30]; HDL metabolism [31:45]; CETP inhibitors for raising HDL-C: does it reduce CVD risk? [34:45]; Why it’s so important to have hard outcome trials in the field of cardiovascular medicine [42:30]; SR-B1: an HDL receptor important for cholesterol efflux [48:00]; The association between HDL levels and atherosclerosis: are they causally linked? [53:15]; How insulin resistance is impacting HDL, and how HDL-C provides insights into triglyceride metabolism [58:00]; Disappointing results from the studies of niacin—a drug that raises HDL-C and lowers apoB [1:08:15]; HDL lipidation, dilapidation, and reverse cholesterol transport [1:12:00]; Measuring the cholesterol efflux capacity of HDL: a better predictor of ASCVD risk than HDL-C? [1:22:00]; A promising new intervention that may promote cholesterol efflux and reverse cholesterol transport [1:32:45]; The association between HDL cholesterol and neurodegenerative diseases [1:34:00]; Challenges ahead, a promising outlook, and the next frontier in lipidology [1:44:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

    • 1 hr 54 min
    The science of strength, muscle, and training for longevity | Andy Galpin, Ph.D. (PART I)

    The science of strength, muscle, and training for longevity | Andy Galpin, Ph.D. (PART I)

    View the Show Notes Page for This Episode
    Become a Member to Receive Exclusive Content
    Sign Up to Receive Peter’s Weekly Newsletter
    Andy Galpin is a Professor of Kinesiology at California State University at Fullerton, where he studies muscle adaptation and applies his research to work with professional athletes. In this episode, Andy sets the foundation for the conversation by discussing the anatomy, microanatomy, and physiology of the muscle, including explaining what it actually means to undergo hypertrophy of the muscle. He then explains the difference between power, strength, speed, and hypertrophy and how those differences relate to what's happening at the cellular level and the functional unit level. Additionally, he discusses energy sources for muscles, the importance of protein for muscle synthesis, the various types of muscle fibers, and the factors that determine one’s makeup of muscle fibers. Finally, Andy wraps the conversation with how he would design a program for an untrained person committed to adding muscle and functional strength for longevity.
    We discuss:
    Andy’s path to expertise in exercise [3:30]; Contrasting strength, power, and force production and how they inform us about training for longevity [9:30]; Muscle energetics: Fuels that provide energy to muscles, and the importance of protein [17:45]; The structure and microanatomy of muscle, muscle fibers, and more [29:30]; Energy demands of skeletal muscle compared to other tissues in the body [39:45]; How a muscle contraction works and why it requires ATP [48:00]; Muscle fibers: modulation between fiber types with movement and changes in fibers with training and aging [53:15]; Andy’s study of twins demonstrating the difference in muscle fibers between a trained and untrained individual [1:02:30]; Microanatomy of fast-twitch and slow-twitch muscle fibers [1:11:15]; Factors that determine one’s makeup of muscle fibers and how adaptable they are with training [1:22:15]; Hypertrophy and what happens at the cellular level when a muscle grows [1:30:00]; How athletes quickly cut water weight and the rehydration process [1:37:30]; Different types of athletes [1:47:30]; Training advice for a hypothetical client who’s untrained and wants to add muscle and functional strength for longevity [1:49:45]; Changes in muscle and muscular function that occur with aging [1:53:45]; Training plan for the hypothetical client [1:59:30]; What drives muscle hypertrophy? [2:12:15]; How to properly incorporate isometric exercises into a workout [2:19:00]; Additional training tips: movement patterns, how to finish a workout, and more [2:25:45]; Ways to incorporate high heart rate exercise into a workout plan [2:28:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

    • 2 hrs 35 min
    AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease

    AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease

    View the Show Notes Page for This Episode
    Become a Member to Receive Exclusive Content
    Sign Up to Receive Peter’s Weekly Newsletter
    In this “Ask Me Anything” (AMA) episode, Peter answers questions related to the leading cause of death in both men and women—atherosclerotic cardiovascular disease (ASCVD). He highlights the most important risk factors for ASCVD, such as apoB, LDL, hyperinsulinemia, and Lp(a), and explains the mechanism by which they confer risk and how these factors are interrelated. Peter also dives deep into the data around apoB to try to answer the question of how much residual risk is conferred for ASCVD through metabolic dysfunction once you correct for apoB. He also looks at the data around lifetime risk reduction of ASCVD in the context of low apoB.
    If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #42 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
    We discuss:
    A racecar analogy for understanding atherosclerotic cardiovascular disease [2:00]; Defining and differentiating apoB and LDL-C [10:00]; The interrelated nature of insulin levels, apoB, triglycerides, and ASCVD parameters [13:00]; Another way that hyperinsulinemia plays a role in endothelial dysfunction [18:00]; Why Peter uses the oral glucose tolerance test (OGTT) with all patients [20:15]; Is there any evidence that hyperinsulinemia is an independent contributor to ASCVD? [23:00]; Thinking through risk in the context of high-fat diets resulting in improved metabolic metrics but with an elevation of apoB/LDL-C [27:30]; Thinking through risk in the context of low apoB but higher than normal triglyceride levels [32:15]; The importance of lowering apoB for reducing ASCVD risk [38:15]; Data on men and women with familial hypercholesterolemia that demonstrates the direct impact of high apoB and LDL-C on ASCVD risk [47:45]; Importance of starting prevention early, calcium scores, and explaining causality [52:30]; Defining Lp(a), its impact on ASCVD risk, and what you should know if you have high Lp(a) [56:30]; Lp(a) and ethnic differences in risk [1:00:30]; Why someone with elevated Lp(a) should consider being more aggressive with apoB lowering strategies [1:05:00]; Addressing the common feeling of hesitancy to taking a pharmacologic approach to lower ASCVD risk [1:07:15]; Peter’s take on the 2022 Formula 1 season and thoughts on 2023 [1:15:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

    • 24 min
    Optimizing life for maximum fulfillment | Bill Perkins

    Optimizing life for maximum fulfillment | Bill Perkins

    View the Show Notes Page for This Episode
    Become a Member to Receive Exclusive Content
    Sign Up to Receive Peter’s Weekly Newsletter
    Bill Perkins is one of the world’s most successful hedge fund managers and entrepreneurs, and the author of the bestseller, Die With Zero. In this episode, Bill unpacks the Die With Zero philosophy which challenges conventional thinking related to the balance between health, wealth, and time—the three variables important for fulfillment. Bill makes the case that we should strive for maximum net fulfillment rather than net worth (or even health). He argues that we need to optimize our life to have memorable experiences before it’s too late and that most people are over-saving and under-living. Bill also explains how one can apply the principles in Die With Zero to break out of “autopilot” and optimize their life to achieve maximum net fulfillment.
    We discuss:
    Bill’s upbringing, background, and first job on Wall Street [3:15]; A missed experience and feeling of regret that shaped Bill’s thinking [14:15]; Thinking in terms of time, and the relationship between money, time, and health [17:00]; Solving for net fulfillment and allocating your time based on the seasons of life [27:15]; How Bill thinks about risk, opportunity costs, and the difference between fear and risk tolerance [35:30]; Optimizing for fulfillment, finding purpose outside of work, and more [41:45]; Thinking about the order of experiences you want to have based on seasons of life [50:00]; Bill’s unique perspective on philanthropy and a more impactful way to give money away [54:45]; Applying the principles in ‘Die With Zero’ to maximize fulfillment [1:04:00]; How to break out of living life on autopilot [1:14:30]; When should your net worth peak? [1:18:00]; Taking calculated risks [1:21:30]; Bill shares a lesson from his incredible birthday [1:25:15]; How Bill’s philosophy has evolved since writing Die With Zero [1:34:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

    • 1 hr 43 min
    Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D.

    Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D.

    View the Show Notes Page for This Episode
    Become a Member to Receive Exclusive Content
    Sign Up to Receive Peter’s Weekly Newsletter
    Kellyann Niotis is a neurologist specializing in risk reduction strategies for the prevention or slowing of neurodegenerative disorders. In this episode, Kellyann provides an overview of the various diseases associated with neurodegeneration, including, but not limited to, Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease. She goes in-depth on Parkinson’s disease, explaining its pathology, role in movement capacity, very early warning signs, and the role of anxiety and sleep. Similarly, she provides an in-depth discussion of Alzheimer’s disease, including the latest in screening, genetics, and tools/strategies for prevention. She ties the discussion together by explaining the differences and commonalities among the various diseases of neurodegeneration and the potential causative triggers, and she highlights the importance of early screening, cognitive testing, and taking the proper steps to lowering the risk of disease.
    We discuss:
    Kellyann’s background, training, and interest in the brain [2:30]; A primer on neurodegeneration: different types, prevalences, interventions, and more [5:30]; Overview of Parkinson’s disease and neuromuscular disorders including ALS [16:00]; Parkinson’s disease: early signs, diagnosis, genetics, causative triggers, and more [17:30]; Interventions to delay or avoid Parkinson’s disease, and the role of sleep and anxiety [31:15]; The challenge of standardizing early interventions for Parkinson’s disease without a clear biomarker [39:45]; Alzheimer’s disease: pathophysiology and the role of the amyloid and tau proteins [47:45]; Can PET scans be informative for diagnosing Alzheimer’s disease? [51:15]; Tau accumulation in the brain, tau scans, serum biomarkers, and possible early detection of Alzheimer’s disease pathology [57:00]; Cognitive testing explained [1:03:30]; The challenge of identifying the stage of the disease and why drugs have not shown efficacy [1:14:45]; The association between hearing loss and dementia [1:17:45]; The relationship between oral health and neurodegenerative diseases [1:21:30]; Genetic risk for Alzheimer’s disease [1:24:45]; What one’s mitochondrial haplotype can reveal about their risk of neurodegenerative disease [1:32:30]; The positive impact of exercise on brain health [1:37:00]; High blood pressure as a risk factor [1:40:00]; Why women are disproportionately affected by Alzheimer’s disease [1:44:15]; Final takeaways: the future of understanding neurodegenerative disease and further reducing risk [1:46:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

    • 1 hr 56 min

Customer Reviews

4.7 out of 5
421 Ratings

421 Ratings

Harpsy71 ,

Fantastic depth of content

Same as the last Aussie who left review - love it - but I’m not cheating on Huberman (like last Aussie 🤪). I will share the love 🙏🏻💜

Queenbubblypiss ,

Love it!

I love this podcast as much as Huberman Lab. Both hosts are smart, articulate and present the best and latest scientific info to their audiences. Peter’s voice is also very easy to listen to, even for an Aussie like me 🤪

dave.nadir ,

Thank you

As a medical practitioner, I find this podcast very informative and educational that covers most ambiguous topics.
Thank you

Top Podcasts In Health & Fitness

Scicomm Media
Hugh van Cuylenburg, Ryan Shelton & Josh van Cuylenburg
Jay Shetty
Mamamia Podcasts
LiSTNR
Rob Dial and Kast Media

You Might Also Like

Rhonda Patrick, Ph.D.
Lifespan Communications LLC
InsideTracker
Ben Greenfield
Author Mike Mutzel interviews Jeff Bland, Datis Kharrazian, Ben Greenfield, Abel James, Dave Asprey, Ben Lynch, Jade Teta and Corey chuler
Dawn Kernagis and Ken Ford